文献速递儿童感染儿童血液肿瘤与免疫

免疫功能受损儿童侵袭性真菌感染:全国研究新见解

Invasive Fungal Infections in Immunocompromised Children: Novel Insight Following a National Study.
PubMed 文献 · J Pediatr · 2021-05-13

该法国多中心回顾性研究纳入2014至2017年2721例接受急性白血病治疗或异基因造血干细胞移植的严重免疫受损儿童,诊断144例侵袭性真菌感染(5.3%),其中念珠菌病61例、曲霉病60例、新兴真菌感染23例。急性髓系白血病患者感染率更高(12.9%),而异基因移植患者中初级抗真菌预防与较低感染率相关,但预防期间主要病原为耐药新兴真菌。

要点

  • 急性髓系白血病患儿侵袭性真菌感染率高于其他患儿。
  • 异基因造血干细胞移植患者中初级抗真菌预防与较低感染率相关。
  • 接受预防的患儿侵袭性真菌感染主要由耐药新兴真菌引起。

核心结论

  • 研究揭示的新兴真菌和新的抗真菌耐药特征应纳入免疫受损儿童侵袭性真菌感染的管理考虑。

研究设计与样本

  • 法国全国多中心回顾性研究收集急性白血病一线或复发治疗中或接受异基因造血干细胞移植的儿童确诊和临床诊断侵袭性真菌感染流行病学数据。
  • 同时开展前瞻性实践调查以提供儿科血液科病房侵袭性真菌感染管理的全国概况。

主要发现

  • 2014年1月至2017年12月,2721例患者中诊断144例侵袭性真菌感染(5.3%),包括61例念珠菌病、60例曲霉病和23例新兴真菌感染(其中10例毛霉病、6例镰刀菌病)。
  • 急性髓系白血病患者侵袭性真菌感染率为12.9%,高于队列其余患者(OR 3.24;95%CI 2.15-4.81;P < .0001)。
  • 接受异基因造血干细胞移植的患者侵袭性真菌感染率仅为4.3%。
  • 在这些患者中,使用初级抗真菌预防(主要为氟康唑)与较低的侵袭性真菌感染率相关(OR 0.28;95%CI 0.14-0.60;P = 4.90 ×10-4)。
  • 接受预防的患儿侵袭性真菌感染主要病原为新兴病原体(41%),如毛霉病和镰刀菌病,对预防药物耐药。

临床怎么用

  • 对严重免疫受损儿童,尤其急性髓系白血病患者,应警惕侵袭性真菌感染风险。
  • 异基因造血干细胞移植患者可考虑初级抗真菌预防,但需注意耐药新兴真菌的可能。
  • 管理侵袭性真菌感染时应考虑新兴真菌和耐药特征。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To obtain a national overview of the epidemiology and management of invasive fungal infections (IFIs) in France for severely immunocompromised children who were treated for acute leukemia or had undergone allogeneic hematopoietic stem cell transplantation (a-HSCT). STUDY DESIGN: We performed a national multicenter retrospective study to collect epidemiologic data for proven and probable IFIs in children with acute leukemia under first- line or relapse treatment or who had undergone a-HSCT. We also conducted a prospective practice survey to provide a national overview of IFI management in pediatric hematology units. RESULTS: From January 2014 to December 2017, 144 cases of IFI were diagnosed (5.3%) in 2721 patients, including 61 cases of candidiasis, 60 cases of aspergillosis, and 23 cases of infection with "emergent" fungi, including 10 cases of mucormycosis and 6 cases of fusariosis. The IFI rate was higher in patients with acute myelogenous leukemia (12.9%) (OR, 3.24; 95% CI, 2.15-4.81; P < .0001) compared with the rest of the cohort. Patients undergoing a-HSCT had an IFI rate of only 4.3%. In these patients, the use of primary antifungal prophylaxis (principally fluconazole) was associated with a lower IFI rate (OR, 0.28; 95% CI, 0.14-0.60; P = 4.90 ×10-4) compared with a-HSCT recipients who did not receive antifungal prophylaxis. The main cause of IFI in children receiving prophylaxis was emergent pathogens (41%), such as mucormycosis and fusariosis, which were resistant to the prophylactic agents. CONCLUSIONS: The emerging fungi and new antifungal resistance profiles uncovered in this study should be considered in IFI management in immunocompromised children.

来源:J Pediatr,查看原文。版权归原作者所有。

引用

  1. Olivier-Gougenheim L, Rama N, Dupont D, et al. Invasive Fungal Infections in Immunocompromised Children: Novel Insight Following a National Study. J Pediatr. 2021. PMID: 33991540. doi:10.1016/j.jpeds.2021.05.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。